{
    "clinical_study": {
        "@rank": "63745", 
        "arm_group": {
            "arm_group_label": "Vismodegib", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study will assess the safety and efficacy of vismodegib in patients with\n      relapsed/refractory acute myelogenous leukemia (AML) and relapsed/refractory high-risk\n      myelodysplastic syndrome (MDS). Patients in Cohort 1 will receive single-agent vismodegib\n      150 mg orally daily. In Cohort 2, patients will receive vismodegib 150 mg orally daily in\n      combination with cytarabine 20 mg subcutaneously for 10 days.\n\n      Anticipated time on study treatment is until disease progression, intolerable toxicity, or\n      patient withdrawal of consent."
        }, 
        "brief_title": "A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myleodysplastic Syndrome", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Myelodysplastic Syndromes, Myelogenous Leukemia, Acute", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Myelodysplastic Syndromes", 
                "Preleukemia", 
                "Acute Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Patients with documented relapsed or refractory AML, except acute promyelocytic\n             leukemia (APL [M3 subtype]), or relapsed or refractory high-risk MDS (high-risk MDS\n             defined as International Prognostic Scoring System (IPSS) Int-2 or high and >/= 10%\n             blasts in bone marrow)\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2\n\n          -  Negative serum pregnancy test for women of childbearing potential and use of two\n             forms of contraception while enrolled in the study and for 7 months after the patient\n             discontinues from study\n\n          -  Male patients with female partners of childbearing potential must agree to use a\n             latex condom and to advise their female partner to use an additional method of\n             contraception during the study and for 2 months after the last dose of vismodegib\n\n          -  All non-hematological adverse events of any prior chemotherapy, surgery, or\n             radiotherapy must have resolved to NCI CTCAE Grade </= 2 prior to starting therapy\n\n          -  Adequate hepatic and renal function\n\n        Exclusion Criteria:\n\n          -  Prior treatment with a Hh pathway inhibitor\n\n          -  Prior therapy for the treatment of malignancy within 14 days of Day 1, with the\n             exception of:\n\n        Hydroxyurea in patients who need to continue this agent to maintain WBC counts </=\n        50,000/mL. Hydroxyurea must be discontinued by Day 14 of the study\n\n          -  Current evidence of active CNS leukemia\n\n          -  Any other active malignancy (except non-melanoma skin cancer or carcinoma in situ of\n             the cervix)\n\n          -  Any severe and/or uncontrolled medical conditions or other conditions that could\n             affect their participation in the study such as:\n\n        Unstable angina, symptomatic or otherwise uncontrolled arrhythmia requiring medication\n        (does not include stable, lone atrial fibrillation), or myocardial infarction </= 6 months\n        before study treatment start Any active (acute or chronic) or uncontrolled\n        infection/disorders that impair the ability to evaluate the patient or for the patient to\n        complete the study\n\n          -  Pregnant or breast-feeding women\n\n          -  Patients who refuse to potentially receive blood products and/or have a severe\n             hypersensitivity to blood products"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01880437", 
            "org_study_id": "GO28852", 
            "secondary_id": "2013-001570-14"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vismodegib", 
                "description": "Cohorts 1 and 2: 150 mg orally daily", 
                "intervention_name": "vismodegib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Vismodegib", 
                "description": "Cohort 2: 20 mg sc daily for 10 days starting Day 1, with a possible further cycle of 20 mg sc daily for 5 days starting no earlier than Day 29", 
                "intervention_name": "cytarabine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Cytarabine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Palo Alto", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64131"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edmonton", 
                        "country": "Canada", 
                        "state": "Alberta", 
                        "zip": "T6L5X8"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 2M9"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H3T 1E2"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H1T 2M4"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Braunschweig", 
                        "country": "Germany", 
                        "zip": "38114"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Essen", 
                        "country": "Germany", 
                        "zip": "45122"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany", 
                        "zip": "20246"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Germany", 
                        "zip": "69120"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "M\u00fcnster", 
                        "country": "Germany", 
                        "zip": "48149"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "Germany"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A PHASE IB/II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VISMODEGIB IN RELAPSED/REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML) AND RELAPSED/REFRACTORY HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: GO28852 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall response rate (CR, CRi or PR) at Week 8", 
            "safety_issue": "No", 
            "time_frame": "Week 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01880437"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall response rate at any time during study treatment", 
                "safety_issue": "No", 
                "time_frame": "approximately 16 months"
            }, 
            {
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "approximately 16 months"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "approximately 16 months"
            }, 
            {
                "measure": "Safety: Incidence of adverse events, according to NCI CTCAE v4.0", 
                "safety_issue": "No", 
                "time_frame": "approximately 16 months"
            }, 
            {
                "measure": "Pharmacokinetics: Steady-state plasma concentration", 
                "safety_issue": "No", 
                "time_frame": "Days 8 and 29"
            }, 
            {
                "measure": "Cohort 2: Pharmacokinetics od cytarabine in combination with vismodegib: Area under the concentration-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Pre- and post-dose Days 1, 8 and 29"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}